Leopold Tientcheu Djomkam

Leopold Tientcheu Djomkam

Auto-generated profile, based on publicly available information

Leopold Tientcheu Djomkam

London School of Hygiene and Tropical Medicine

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2015 in Genes & Immunity
Verified
Journal Article
Open access
PDF file
LTL D Tientcheu
L D Tientcheu
JMJ Maertzdorf
J Maertzdorf
JWJ Weiner
J Weiner
IAI M Adetifa
I M Adetifa
HMH-J Mollenkopf
H-J Mollenkopf
MOM O Ota
M O Ota
The epidemiology of Mycobacterium tuberculosis (Mtb) and M. africanum (Maf) suggests differences in their virulence, but the host immune profile to better understand the pathogenesis of tuberculosis (TB) have not been studied. We compared the transcriptomic and metabolic profiles between Mtb- and Maf-infected TB cases to identify host biomarkers associated with lineages-specific pathogenesis and response to anti-TB chemotherapy. Venous blood samples from Mtb- and Maf-infected patients obtained before and after anti-TB treatment were analyzed for cell composition, gene expression and metabolic profiles. Prior to treatment, similar transcriptomic profiles were seen in Maf- and Mtb-infected patients. In contrast, post treatment, over 1600 genes related to immune responses and metabolic diseases were differentially expressed between the groups. Notably, the upstream regulator hepatocyte nuclear factor 4-alpha (HNF4α), which regulated 15% of these genes, was markedly enriched. Serum metabolic profiles were similar in both group pre-treatment, but the decline in pro-inflammatory metabolites post treatment were most pronounced in Mtb-infected patients. Together, the differences in both peripheral blood transcriptomic and serum metabolic profiles between Maf- and Mtb-infected patients observed over the treatment period, might be indicative of intrinsic host factors related to susceptibility to TB and/or differential efficacy of the standard anti-TB treatment on the two lineages.

18 May 2016 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
LTLeopold D. Tientcheu
Leopold D. Tientcheu
MHMariëlle C. Haks
Mariëlle C. Haks
SASchadrac C. Agbla
Schadrac C. Agbla
JSJayne S. Sutherland
Jayne S. Sutherland
IAIfedayo M. Adetifa
Ifedayo M. Adetifa
MOMartin O. Ota
Martin O. Ota
Epidemiological differences exist between Mycobacterium africanum (Maf)- and Mycobacterium tuberculosis (Mtb)-infected patients, but to date, contributing host factors have not been characterised. We analysed clinical outcomes, as well as soluble markers and gene expression profiles in unstimulated, and ESAT6/CFP-10-, whole-Maf- and Mtb-stimulated blood samples of 26 Maf- and 49 Mtb-HIV-negative tuberculosis patients before, and after 2 and 6 months of anti-tuberculosis therapy. Before treatment, both groups had similar clinical parameters, but differed in few cytokines concentration and gene expression profiles. Following treatment the body mass index, skinfold thickness and chest X-ray scores showed greater improvement in the Mtb- compared to Maf-infected patients, after adjusting for age, sex and ethnicity (p = 0.02; 0.04 and 0.007, respectively). In addition, in unstimulated blood, IL-12p70, IL12A and TLR9 were significantly higher in Maf-infected patients, while IL-15, IL-8 and MIP-1α were higher in Mtb-infected patients. Overnight stimulation with ESAT-6/CFP-10 induced significantly higher levels of IFN-γ and TNF-α production, as well as gene expression of CCL4, IL1B and TLR4 in Mtb- compared to Maf-infected patients. Our study confirms differences in clinical features and immune genes expression and concentration of proteins associated with inflammatory processes between Mtb- and Maf-infected patients following anti-tuberculosis treatment These findings have public health implications for treatment regimens, and biomarkers for tuberculosis diagnosis and susceptibility. In the Gambia tuberculosis is caused my two major lineages within the Mycobacterium tuberculosis complex (MTBC), M. tuberculosis lineages 4 and M. africanum lineage 6. Our analysis of 26 M. africanum- and 49 M. tuberculosis -HIV-negative tuberculosis patients’ clinic parameters and antigen-stimulated blood cytokines concentration and genes expression reveal that heterogeneous response to standard anti-tuberculosis treatment might depend on the diversity of MTBC lineages. Before treatment, the two groups of patients had similar clinical parameters, but greater improvement was observed in M. tuberculosis- compared to M. africanum -infected patients post-treatment. This was supported by higher production of inflammation-associated cytokines and genes in unstimulated blood samples from M. africanum-infected patients compared to those infected with M. tuberculosis, who instead had higher level of disease resolution cytokines. In contrast, there were lower cytokine responses in antigen-stimulated blood samples of M. africanum- compared to M. tuberculosis-infected patients post-treatment indicating a poorly recovered immune profile. Our results suggest that M. africanum patients respond relatively poorly to the standard anti-tuberculosis treatment or might have a pre-existing defective immune profile; this could explain why they succumb to less virulent mycobacteria.

20 February 2014 in European Journal of Immunology
Verified
Journal Article
Closed access
PDF file
LTLeopold D. Tientcheu
Leopold D. Tientcheu
JSJayne S. Sutherland
Jayne S. Sutherland
BJBouke C. de Jong
Bouke C. de Jong
BKBeate Kampmann
Beate Kampmann
JJJames Jafali
James Jafali
MOMartin O. Ota
Martin O. Ota

29 April 2020 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NANicholas J. Andreas
Nicholas J. Andreas
RRRobindra Basu Roy
Robindra Basu Roy
MGMaria Gomez-Romero
Maria Gomez-Romero
VSVerena Horneffer-Van der Sluis
Verena Horneffer-Van der Sluis
MLMatthew R. Lewis
Matthew R. Lewis
BKBeate Kampmann
Beate Kampmann
We applied a metabonomic strategy to identify host biomarkers in serum to diagnose paediatric tuberculosis (TB) disease. 112 symptomatic children with presumptive TB were recruited in The Gambia and classified as bacteriologically-confirmed TB, clinically diagnosed TB, or other diseases. Sera were analysed using 1H nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry (MS). Multivariate data analysis was used to distinguish patients with TB from other diseases. Diagnostic accuracy was evaluated using Receiver Operating Characteristic (ROC) curves. Model performance was tested in a validation cohort of 36 children from the UK. Data acquired using 1H NMR demonstrated a sensitivity, specificity and Area Under the Curve (AUC) of 69% (95% confidence interval [CI], 56–73%), 83% (95% CI, 73–93%), and 0.78 respectively, and correctly classified 20% of the validation cohort from the UK. The most discriminatory MS data showed a sensitivity of 67% (95% CI, 60–71%), specificity of 86% (95% CI, 75–93%) and an AUC of 0.78, correctly classifying 83% of the validation cohort. Amongst children with presumptive TB, metabolic profiling of sera distinguished bacteriologically-confirmed and clinical TB from other diseases. This novel approach yielded a diagnostic performance for paediatric TB comparable to that of Xpert MTB/RIF and interferon gamma release assays.

1 December 2016 in International Journal of Mycobacteriology
Verified
Journal Article
Open access
LTLeopold D. Tientcheu
Leopold D. Tientcheu
ABAndrew Bell
Andrew Bell
OSOumie Secka
Oumie Secka
AAAbigail Ayorinde
Abigail Ayorinde
JOJacob Otu
Jacob Otu
MBMichael R. Barer
Michael R. Barer
Objectives/Background: Mycobacterium africanum that causes 40% of tuberculosis (TB) in West Africa grows more slowly in culture and has similar transmission capacity compared with Mycobacterium tuberculosis , but M. africanum -exposed contacts progress more slowly to active disease. The presence of lipid body (LB) containing M. tuberculosis complex (MTBC) cells in sputum samples has been associated with mycobacterial transcriptomes indicating slow or no growth and persister-like antibiotic tolerance. Slow-growing bacilli have been found to display a persister-like phenotype with the accumulation of LBs and drug tolerance. Our previous study showed that the body mass index and lung damage resolution on chest X-ray were significantly improved slower in M. africanum -infected patients posttreatment than in M. tuberculosis -infected patients; however, the reason for this remains unclear. Therefore, we hypothesized that these differences could be either due to significant differences in drug resistance between the MTBC lineages or a difference in their content of persisters, as indicated by the percentage of LP-positive bacilli in sputum. Methods: Sputum isolates collected before treatment from patients with TB were subjected to drug susceptibility testing using the BD BACTEC MGIT 960 SIRE kit. The percentage of acid-fast bacilli (AFB) and LB-positive bacilli in pretreatment sputum was determined by a dual staining procedure using Auramine O and LipidTOX Red neutral lipid stain, respectively, and fluorescence microscopy imaging. Results: Out of the 77 isolates tested, 9 showed resistance to at least one drug and only 2 showed multidrug (rifampicin and isoniazid) resistance among M. tuberculosis -infected patients. The percentage of AFB-positive smears was similar between the two groups ( p = 0.821), whereas that of LP-positive bacilli was significantly higher ( p = 0.0059) in M. africanum-infected patients' sputa ( n = 24) than in M. tuberculosis -infected patients' sputa ( n = 36). In addition, the bacillary lengths were significantly higher in M. africanum -infected patients' sputa than in M. tuberculosis -infected patients' sputa ( p = 0.0007). A high frequency of LP-positive bacilli in pretreatment sputum was associated with a poor body mass index and lung damage on chest X-ray improvement following anti-TB treatment in both the groups (r 2 = 0.022; p = 0.017). Conclusion: The slow clinical recovery of M. africanum -infected patients compared with M. tuberculosis -infected patients posttreatment may be at least partially associated with the persistence of drug-tolerant “fat and lazy” bacilli.

2 July 2020 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
WLW. van Loon
W. van Loon
MGM. P. Gomez
M. P. Gomez
DJD. Jobe
D. Jobe
KFK. L. M. C. Franken
K. L. M. C. Franken
TOT. H. M. Ottenhoff
T. H. M. Ottenhoff
LTL. D. Tientcheu
L. D. Tientcheu
Background: Interferon-γ release assays (IGRA) with Resuscitation promoting factor (Rpf) proteins enhanced tuberculosis (TB) screening and diagnosis in adults but have not been evaluated in children. Children often develop paucibacillary TB and their immune response differs from that of adults, which together affect TB disease diagnostics and immunodiagnostics. We assessed the ability of Rpf to identify infection among household TB-exposed children in The Gambia and investigated their ability to discriminate Mycobacterium tuberculosis complex (MTBC) infection from active TB disease in children. Methods: Detailed clinical investigations were done on 93 household TB-exposed Gambian children and a tuberculin skin test (TST) was administered to asymptomatic children. Venous blood was collected for overnight stimulation with ESAT-6/CFP-10-fusion protein (EC), purified protein derivative and RpfA, B, C, D and E. Interferon gamma (IFN-γ) production was measured by ELISA in supernatants and corrected for the background level. Infection status was defined by IGRA with EC and TB disease by mycobacterial confirmation and/or clinical diagnosis. We compared IFN-γ levels between infected and uninfected children and between infected and TB diseased children using a binomial logistic regression model while correcting for age and sex. A Receiver Operating Characteristics analysis was done to find the best cut-off for IFN-γ level and calculate sensitivity and specificity. Results: Interferon gamma production was significantly higher in infected (IGRA+, n = 45) than in uninfected (IGRA-, n = 20) children after stimulation with RpfA, B, C, and D (P = 0.03; 0.007; 0.03 and 0.003, respectively). Using RpfB and D-specific IFN-γ cut-offs (33.9 pg/mL and 67.0 pg/mL), infection was classified with a sensitivity-specificity combination of 73–92% and 77–72% respectively, which was similar to and better than 65–75% for TST. Moreover, IFN-γ production was higher in infected than in TB diseased children (n = 28, 5 bacteriologically confirmed, 23 clinically diagnosed), following RpfB and D stimulation (P = 0.02 and 0.03, respectively). Conclusion: RpfB and RpfD show promising results for childhood MTBC infection screening, and both performed similar to and better than the TST in our study population. Additionally, both antigens appear to discriminate between infection and disease in children and thus warrant further investigation as screening and diagnostic antigens for childhood TB.